Vertex Pharmaceuticals Inc. and Alexion Pharmaceuticals Inc. stock underperforms

The Shares of Vertex Pharmaceuticals Inc. slumped 0.33% to $213.16 Thursday. This proved to be an all-around positive trading session for the Stock market, with the S&P 500 Index SPX rising 0.82% to 4,201.62 and the Dow Jones Industrial Average DJIA rising 0.93% to 34,548.53. This was the stock’s fourth consecutive day of losses.

The Shares of Alexion Pharmaceuticals Inc. ALXN sank 0.03% to $169.86 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 4,201.62 and the Dow Jones Industrial Average DJIA rising 0.93% to 34,548.53. Alexion Pharmaceuticals Inc. closed $2.22 below its 52-week high ($172.08), which the company reached on April 30th

Vertex Pharmaceuticals Inc. closed $92.92 short of its 52-week high ($306.08), which the company achieved on July 7th. The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson JNJ rose 0.40% to $167.74, Merck & Co. Inc. MRK rose 0.10% to $77.78, and AbbVie Inc. ABBV rose 0.26% to $116.08. Trading volume (1.2 M) remained 573,719 below its 50-day average volume of 1.8 M.

The stock showed a mixed performance when compared to some of its competitors Thursday, as Gilead Sciences Inc. GILD rose 0.05% to $66.54, Vertex Pharmaceuticals Inc. VRTX dropped 0.33% to $213.16, and Regeneron Pharmaceuticals Inc. REGN rose 3.37% to $498.68. Trading volume (1.6 M) remained 824,706 below its 50-day average volume of 2.4 M.